WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140126) METHOD OF ADMINISTERING A THERAPEUTIC
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140126    International Application No.:    PCT/US2009/043065
Publication Date: 19.11.2009 International Filing Date: 07.05.2009
IPC:
C12Q 1/68 (2006.01), A61K 38/24 (2006.01), A61P 5/24 (2006.01), A61P 15/00 (2006.01)
Applicants: WARD, Kenneth [US/US]; (US).
JUNEAU BIOSCIENCES, LLC [US/US]; 2749 Parleys Way Suite 210 Salt Lake City, UT 84109 (US) (For All Designated States Except US)
Inventors: WARD, Kenneth; (US)
Agent: SCHRAMM, Michael, R.; 2749 East Parleys Way Suite 200 Salt Lake City, UT 84109 (US)
Priority Data:
12/120,322 14.05.2008 US
61/171,717 22.04.2009 US
Title (EN) METHOD OF ADMINISTERING A THERAPEUTIC
(FR) PROCÉDÉ D’ADMINISTRATION D’UN AGENT THÉRAPEUTIQUE
Abstract: front page image
(EN)The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a hormonal treatment such as a combined estrogen/progestin therapeutic which specifically includes an oral contraceptive that at least partially prevents or compensates for an endometriosis related symptom.
(FR)La présente invention concerne de nouveaux marqueurs génétiques associés à l’endométriose et au risque de développement d’endométriose, et des procédés et des matériaux pour déterminer si un sujet humain a une endométriose ou présente un risque de développer une endométriose et l’utilisation de telles informations de risque dans l’administration sélective d’un traitement hormonal tel qu’un agent thérapeutique combiné œstrogène/progestatif qui comprend spécifiquement un contraceptif oral qui prévient ou atténue au moins partiellement un symptôme associé à l’endométriose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)